Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.52
ISIS's Cash to Debt is ranked higher than
61% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ISIS: 2.52 )
ISIS' s 10-Year Cash to Debt Range
Min: 0.24   Max: 7.99
Current: 2.52

0.24
7.99
Equity to Asset 0.43
ISIS's Equity to Asset is ranked higher than
60% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ISIS: 0.43 )
ISIS' s 10-Year Equity to Asset Range
Min: -0.85   Max: 0.76
Current: 0.43

-0.85
0.76
F-Score: 2
Z-Score: 8.99
M-Score: -1.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -45.27
ISIS's Operating margin (%) is ranked higher than
76% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ISIS: -45.27 )
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91   Max: -12.18
Current: -45.27

-438.91
-12.18
Net-margin (%) -54.98
ISIS's Net-margin (%) is ranked higher than
75% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. ISIS: -54.98 )
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33   Max: 127.52
Current: -54.98

-334.33
127.52
ROE (%) -25.28
ISIS's ROE (%) is ranked higher than
76% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ISIS: -25.28 )
ISIS' s 10-Year ROE (%) Range
Min: -280.13   Max: 86.43
Current: -25.28

-280.13
86.43
ROA (%) -11.29
ISIS's ROA (%) is ranked higher than
81% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ISIS: -11.29 )
ISIS' s 10-Year ROA (%) Range
Min: -59.44   Max: 25.19
Current: -11.29

-59.44
25.19
ROC (Joel Greenblatt) (%) -85.75
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. ISIS: -85.75 )
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -800.86   Max: -58.29
Current: -85.75

-800.86
-58.29
Revenue Growth (3Y)(%) 6.90
ISIS's Revenue Growth (3Y)(%) is ranked higher than
83% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ISIS: 6.90 )
ISIS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -39.4   Max: 83.7
Current: 6.9

-39.4
83.7
EBITDA Growth (3Y)(%) -4.50
ISIS's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ISIS: -4.50 )
ISIS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.6   Max: 61.3
Current: -4.5

-49.6
61.3
EPS Growth (3Y)(%) -3.90
ISIS's EPS Growth (3Y)(%) is ranked higher than
79% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ISIS: -3.90 )
ISIS' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.2   Max: 117.8
Current: -3.9

-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ISIS Guru Trades in Q4 2013

Murray Stahl 17,000 sh (unchged)
Jim Simons 326,114 sh (-0.85%)
Steven Cohen 8,531 sh (-87.34%)
» More
Q1 2014

ISIS Guru Trades in Q1 2014

George Soros 5,539 sh (New)
Ron Baron 45,251 sh (New)
Steven Cohen 74,106 sh (+768.67%)
Murray Stahl 17,000 sh (unchged)
Jim Simons 136,914 sh (-58.02%)
» More
Q2 2014

ISIS Guru Trades in Q2 2014

Murray Stahl 17,000 sh (unchged)
Ron Baron Sold Out
George Soros Sold Out
Jim Simons Sold Out
» More
Q3 2014

ISIS Guru Trades in Q3 2014

Murray Stahl 17,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-06-30 Sold Out 0.01%$22.98 - $43.33 $ 63.65102%0
George Soros 2014-06-30 Sold Out $22.98 - $43.33 $ 63.65102%0
Ron Baron 2014-03-31 New Buy0.01%$38.56 - $59 $ 63.6532%45251
George Soros 2014-03-31 New Buy$38.56 - $59 $ 63.6532%5539
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 21.72
ISIS's P/B is ranked higher than
60% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ISIS: 21.72 )
ISIS' s 10-Year P/B Range
Min: 3   Max: 1710
Current: 21.72

3
1710
P/S 43.60
ISIS's P/S is ranked higher than
72% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. ISIS: 43.60 )
ISIS' s 10-Year P/S Range
Min: 4.33   Max: 84.47
Current: 43.6

4.33
84.47
EV-to-EBIT -92.22
ISIS's EV-to-EBIT is ranked lower than
51% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ISIS: -92.22 )
ISIS' s 10-Year EV-to-EBIT Range
Min: -198.4   Max: 596.9
Current: -92.22

-198.4
596.9
Current Ratio 6.35
ISIS's Current Ratio is ranked higher than
80% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ISIS: 6.35 )
ISIS' s 10-Year Current Ratio Range
Min: 2.49   Max: 9.89
Current: 6.35

2.49
9.89
Quick Ratio 6.28
ISIS's Quick Ratio is ranked higher than
80% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ISIS: 6.28 )
ISIS' s 10-Year Quick Ratio Range
Min: 2.49   Max: 9.89
Current: 6.28

2.49
9.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 52.60
ISIS's Price/Net Cash is ranked higher than
74% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. ISIS: 52.60 )
ISIS' s 10-Year Price/Net Cash Range
Min: 4.75   Max: 403.13
Current: 52.6

4.75
403.13
Price/Net Current Asset Value 45.14
ISIS's Price/Net Current Asset Value is ranked higher than
72% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. ISIS: 45.14 )
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 4.69   Max: 844.5
Current: 45.14

4.69
844.5
Price/Tangible Book 23.06
ISIS's Price/Tangible Book is ranked higher than
64% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. ISIS: 23.06 )
ISIS' s 10-Year Price/Tangible Book Range
Min: 1.83   Max: 216.67
Current: 23.06

1.83
216.67
Price/Median PS Value 3.61
ISIS's Price/Median PS Value is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ISIS: 3.61 )
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.35
Current: 3.61

0.21
5.35
Earnings Yield (Greenblatt) -1.10
ISIS's Earnings Yield (Greenblatt) is ranked higher than
84% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. ISIS: -1.10 )
ISIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 0.3
Current: -1.1

0.2
0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISI.Germany,
Isis Pharmaceuticals was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business consists of Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 31 drugs in development. Company's ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company's drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
» More Articles for ISIS

Headlines

Articles On GuruFocus.com
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 26 2014
Biotech Bull Markets and Billion-Dollar Valuations Dec 23 2014
Cramer's Mad Dash: Tale of two biotechs Dec 19 2014
Jim Cramer's Top Stock Picks: BA MMM ISIS Q Dec 19 2014
Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally Dec 18 2014
Cramer: One of the most exciting stocks I've seen Dec 18 2014
Isis Pharmaceuticals' game-changer drug Dec 18 2014
Stock Pops & Drops: SPWR, CROX, GOOGL & ISIS Dec 16 2014
Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy... Dec 16 2014
Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy... Dec 16 2014
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices Dec 10 2014
ISIS Jumps on Positive Results for Venous Thrombosis Drug Dec 09 2014
Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4% Dec 08 2014
Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences,... Dec 08 2014
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous... Dec 07 2014
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous... Dec 07 2014
Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award Dec 05 2014
Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award Dec 05 2014
Earnings Estimates Moving Higher for Isis Pharmaceuticals (ISIS): Time to Buy? Dec 04 2014
ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England... Dec 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK